PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-2.48%
Revenue decline while Drug Manufacturers - Specialty & Generic median is 2.16%. Seth Klarman would investigate if market share loss is temporary.
2.66%
Cost growth near Drug Manufacturers - Specialty & Generic median of 2.66%. Charlie Munger would verify if industry cost structure is attractive.
-18.23%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is 1.74%. Seth Klarman would investigate competitive position.
-16.16%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-42.29%
R&D reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
53.56%
G&A change of 53.56% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
-7.15%
Marketing expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
-231.01%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
49.13%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.26%. Jim Chanos would check for waste.
18.08%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.21%. Jim Chanos would check for waste.
64.38%
Interest expense change of 64.38% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
-9.04%
D&A reduction while Drug Manufacturers - Specialty & Generic median is 0.45%. Seth Klarman would investigate efficiency.
-6043.79%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is -2.39%. Seth Klarman would investigate causes.
64.56%
Margin change of 64.56% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-61.11%
Operating income decline while Drug Manufacturers - Specialty & Generic median is -0.10%. Seth Klarman would investigate causes.
-65.20%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-194.63%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 5.73%. Seth Klarman would investigate advantages.
-159.99%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 3.15%. Seth Klarman would investigate causes.
-166.59%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
133.92%
Tax expense change of 133.92% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify strategy.
-205.02%
Net income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-212.77%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-181.58%
EPS decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-181.58%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
9.00%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.06%. Jim Chanos would check for issues.
9.00%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would check for issues.